<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156645</url>
  </required_header>
  <id_info>
    <org_study_id>SCTA01/SCTA01C-A301</org_study_id>
    <nct_id>NCT05156645</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 &amp; SCTA01C in Outpatients With COVID-19</brief_title>
  <official_title>An Adaptive Phase I/II/III Trial to Evaluate the Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibody Combination (SCTA01C and SCTA01) for Treatment of Outpatients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal&#xD;
      study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 &amp; SCTA01C&#xD;
      compared to placebo in addition to Standard of Care (SOC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29 (Phase III)</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with ≥Grade 3 treatment related adverse event (TRAE) up to Day 8 (Phase I/II)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sustained resolution of all COVID-19-related symptoms</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom score (total of ratings)</measure>
    <time_frame>Day 3, 5, 7, 11, 15, 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom improvement</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that achieve SARS-CoV-2 clearance in NP or OP samples</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment includes the number and percentage of patients who develop detectable anti drug antibody</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean concentration-time profiles of SCTA01 and SCTA01C</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">434</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>SCTA01 and SCTA01C+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCTA01 and SCTA01C</intervention_name>
    <description>Diluted by 0.9% normal saline</description>
    <arm_group_label>SCTA01 and SCTA01C+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluted by 0.9% normal saline</description>
    <arm_group_label>Placebo+SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female adults, ≥18 years old of age at the time of randomization;&#xD;
&#xD;
          -  Participants should have at least one of COVID-19 risk factor;&#xD;
&#xD;
          -  Participants should have at least 2 COVID-19 related symptoms;&#xD;
&#xD;
          -  Has symptoms consistent with COVID-19 as determined by the investigator with onset ≤10&#xD;
             days before randomization;&#xD;
&#xD;
          -  First positive SARS-CoV-2 viral infection tested (PCR or antigen-based diagnostic&#xD;
             tests) in samples collected ≤5 days prior to start of the infusion;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with a history of severe anaphylaxis, such as severe anaphylactic&#xD;
             reaction, urticaria, and angioedema;&#xD;
&#xD;
          -  Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 &lt; 300, respiratory rate ≥30 per&#xD;
             minute, heart rate ≥125 per minute (FDA);&#xD;
&#xD;
          -  Require mechanical ventilation or anticipated impending need for mechanical&#xD;
             ventilation;&#xD;
&#xD;
          -  Suspected or proven serious bacterial, fungal, viral, or other infection (besides&#xD;
             COVID-19) that in the opinion of the investigator could constitute a risk when taking&#xD;
             part in this study;&#xD;
&#xD;
          -  Have any serious concomitant systemic disease, condition or disorder that, in the&#xD;
             opinion of the investigator, should preclude participation in this study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reborn Luo</last_name>
    <phone>137 5189 1764</phone>
    <email>zibin_luo@sinocelltech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zixin Li</last_name>
    <phone>177 2404 8318</phone>
    <email>zixin_li@sinocelltech.com</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

